Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Crossref DOI link: https://doi.org/10.1136/jitc-2019-000146
Published Online: 2020-02-26
Published Print: 2020-02
Update policy: https://doi.org/10.1136/crossmarkpolicy
Mulkey, Flora https://orcid.org/0000-0003-0760-2648
Theoret, Marc R
Keegan, Patricia
Pazdur, Richard
Sridhara, Rajeshwari
License valid from 2020-02-26
